Brick & Kyle Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-32,631
| Closed | -$3.02M | – | 62 |
|
|
2024
Q2 | $3.02M | Sell |
32,631
-240
| -0.7% | -$21.5K | 1.25% | 31 |
|
|
2024
Q1 | $2.99M | Sell |
32,871
-425
| -1% | -$39.4K | 1.33% | 31 |
|
|
2023
Q4 | $2.97M | Sell |
33,296
-237
| -0.7% | -$17.6K | 1.48% | 31 |
|
|
2023
Q3 | $2.45M | Sell |
33,533
-200
| -0.6% | -$16K | 1.3% | 32 |
|
|
2023
Q2 | $2.8M | Sell |
33,733
-280
| -0.8% | -$23.4K | 1.5% | 27 |
|
|
2023
Q1 | $2.59M | Buy |
34,013
+618
| +2% | +$51.3K | 1.48% | 29 |
|
|
2022
Q4 | $2.77M | Buy |
33,395
+115
| +0.3% | +$9.31K | 1.61% | 29 |
|
|
2022
Q3 | $2.66M | Buy |
33,280
+115
| +0.3% | +$9.7K | 1.61% | 29 |
|
|
2022
Q2 | $2.44M | Buy |
33,165
+90
| +0.3% | +$6.76K | 1.37% | 34 |
|
|
2022
Q1 | $2.97M | Buy |
33,075
+1,656
| +5% | +$153K | 1.44% | 31 |
|
|
2021
Q4 | $3.52M | Hold |
31,419
| – | – | 1.64% | 27 |
|
|
2021
Q3 | $3.98M | Buy |
31,419
+62
| +0.2% | +$7.98K | 2.02% | 20 |
|
|
2021
Q2 | $4.29M | Sell |
31,357
-188
| -0.6% | -$24.7K | 2.24% | 20 |
|
|
2021
Q1 | $4.34M | Sell |
31,545
-149
| -0.5% | -$22.3K | 2.4% | 17 |
|
|
2020
Q4 | $4.47M | Sell |
31,694
-415
| -1% | -$53.2K | 2.79% | 12 |
|
|
2020
Q3 | $3.58M | Buy |
32,109
+152
| +0.5% | +$17K | 2.47% | 16 |
|
|
2020
Q2 | $3.55M | Buy |
31,957
+415
| +1% | +$40.9K | 2.64% | 14 |
|
|
2020
Q1 | $2.44M | Buy |
+31,542
| New | +$2.79M | 2.29% | 20 |
|
|
2019
Q4 | – | Sell |
-8,748
| Closed | -$722K | – | 71 |
|
|
2019
Q3 | $722K | Sell |
8,748
-675
| -7% | -$56.1K | 0.6% | 39 |
|
|
2019
Q2 | $813K | Buy |
+9,423
| New | +$804K | 0.77% | 34 |
|
|
2019
Q1 | – | Sell |
-9,548
| Closed | -$685K | – | 92 |
|
|
2018
Q4 | $685K | Buy |
+9,548
| New | +$769K | 0.65% | 45 |
|
|
2018
Q2 | $918K | Buy |
9,648
+75
| +0.8% | +$6.89K | 0.72% | 43 |
|
|
2018
Q1 | $840K | Sell |
9,573
-100
| -1% | -$9.13K | 0.68% | 45 |
|
|
2017
Q4 | $821K | Buy |
9,673
+575
| +6% | +$48.2K | 0.67% | 46 |
|
|
2017
Q3 | $788K | Buy |
9,098
+500
| +6% | +$40.1K | 0.64% | 49 |
|
|
2017
Q2 | $664K | Sell |
8,598
-600
| -7% | -$42.6K | 0.57% | 51 |
|
|
2017
Q1 | $638K | Hold |
9,198
| – | – | 0.49% | 53 |
|
|
2016
Q4 | $544K | Buy |
9,198
+100
| +1% | +$6.17K | 0.44% | 55 |
|
|
2016
Q3 | $603K | Hold |
9,098
| – | – | 0.48% | 52 |
|
|
2016
Q2 | $492K | Buy |
9,098
+450
| +5% | +$24.7K | 0.4% | 58 |
|
|
2016
Q1 | $447K | Buy |
8,648
+150
| +2% | +$7.79K | 0.39% | 58 |
|
|
2015
Q4 | $597K | Hold |
8,498
| – | – | 0.53% | 50 |
|
|
2015
Q3 | $529K | Sell |
8,498
-2,890
| -25% | -$228K | 0.5% | 51 |
|
|
2015
Q2 | $958K | Sell |
11,388
-75
| -0.7% | -$5.83K | 0.8% | 40 |
|
|
2015
Q1 | $862K | Buy |
11,463
+2,118
| +23% | +$148K | 0.74% | 40 |
|
|
2014
Q4 | $581K | Buy |
+9,345
| New | +$533K | 0.5% | 50 |
|
Other funds holding XBI
Brick & Kyle Associates's XBI Position: Q3 2024 in Review
Brick & Kyle Associates sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 32,631 shares — an estimated $3.02M sold.
Brick & Kyle Associates first reported a position in XBI in Q4 2014 and held it in 36 quarters. The position peaked at $4.47M in Q4 2020. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.
- Brick & Kyle Associates reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
- Brick & Kyle Associates sold 32,631 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $3.02M.
- Brick & Kyle Associates first reported a position in State Street SPDR S&P Biotech ETF in Q4 2014 and held it in 36 quarters.
- Brick & Kyle Associates's State Street SPDR S&P Biotech ETF position peaked at $4.47M in Q4 2020.
- 769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.
Based on Brick & Kyle Associates's 13F filing for Q3 2024, filed 14 Nov 2024.